Form 4: Galectin CEO Exercises Options, Sells Shares

Galectin Therapeutics Inc.'s President and CEO, Joel Lewis, exercised stock options and subsequently sold an equal number of common shares under a pre-arranged 10b5-1 plan.

Summary

• Joel Lewis, President and CEO of Galectin Therapeutics Inc., exercised 7,829 stock options at an exercise price of $2.86 per share on December 17, 2025.
• Concurrently, Lewis sold 7,829 shares of common stock at a weighted average price of $7.056 per share on December 17, 2025.
• These transactions were executed as part of a Rule 10b5-1 trading plan adopted on April 17, 2025, which was disclosed in the Issuer's Quarterly Report on Form 10-Q filed on August 14, 2025.
• Following these transactions, Lewis directly owns 832,592 shares of common stock.
• Lewis also indirectly holds 2,000 shares as custodian for a minor child under the Uniform Transfer to Minors Act, disclaiming beneficial ownership of these shares.
• After the option exercise, Lewis beneficially owns 32,171 stock options.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine exercise and sale under a pre-arranged 10b5-1 plan, which typically does not signal strong positive or negative sentiment about the company's immediate future. It represents a planned liquidity event for the executive.

Positives

• The sale of shares was executed at a significantly higher price ($7.056 per share) than the option exercise price ($2.86 per share), indicating a profitable transaction for the CEO.
• The transaction was conducted under a pre-arranged Rule 10b5-1 plan, suggesting a planned liquidity event rather than a reaction to immediate company-specific news or market conditions.

Negatives

• A reduction in direct beneficial ownership of common stock by 7,829 shares, although this was a result of exercising options and immediately selling the acquired shares.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Management Comments

• The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.
• The Reporting Person disclaims beneficial ownership of these securities [held as custodian for a minor child], and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Industry Context

This filing details an individual executive's compensation-related transaction and does not provide information directly related to broader industry trends or competitive landscape.

Related Party Transactions

• Joel Lewis holds 2,000 shares indirectly as custodian for a minor child under the Uniform Transfer to Minors Act, though he disclaims beneficial ownership of these shares.

Stakeholder Impact

• Shareholders: The CEO's profitable exercise and sale of shares could be viewed as the executive realizing value from their compensation. While it reduces direct insider ownership, the pre-planned nature of the transaction under a 10b5-1 plan generally mitigates concerns about insider sentiment.

Key Dates

Recommendation

The Form 4 filing details a routine, pre-planned exercise of stock options and subsequent sale of shares by the CEO under a Rule 10b5-1 plan. This type of transaction is generally considered a planned liquidity event for the executive and does not typically signal a change in the company's fundamental outlook or warrant a strong buy or sell recommendation based solely on this filing. The CEO still retains a significant direct and indirect stake in the company. Therefore, a 'hold' recommendation is appropriate as this filing provides no new material information to alter an existing investment thesis.

Keywords

Galectin Therapeutics, GALT, Joel Lewis, Insider Transaction, Form 4, Stock Options, Share Sale, CEO, Rule 10b5-1, Beneficial Ownership